<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584194</url>
  </required_header>
  <id_info>
    <org_study_id>A-12592</org_study_id>
    <secondary_id>FY03-05</secondary_id>
    <nct_id>NCT00584194</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Rift Valley Fever Vaccine</brief_title>
  <acronym>RVF</acronym>
  <official_title>Parts A&amp;B: Evaluation of the Safety and Immunogenicity of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200), A Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the safety and immunogenicity of a Rift Valley Fever
      (RVF) Vaccine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives:

      The objectives of this two-part, primary immunization and booster dose, study are to continue
      to collect safety data on Rift Valley Fever (RVF) Vaccine, Inactivated (TSI-GSD 200); and, to
      continue to collect immunogenicity data on Rift Valley Fever (RVF) Vaccine, Inactivated
      (TSI-GSD 200) and analyze interim data to determine whether a 6-month dose is indicated; and,
      to provide potential protection for personnel at risk for occupational exposure to the RVF
      virus and collect data on incidence of occupational RVF infection (subclinical and clinical)
      in immunized personnel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: All Incidences of Erythema</measure>
    <time_frame>12 months</time_frame>
    <description>Collect data on the occurrence of AEs and SAEs in reference to Erythema (most frequently reported AE) in parts A and B of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Geometric Mean Titers After 3rd Vaccination</measure>
    <time_frame>28 days after dose 3</time_frame>
    <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) antibodies to RVF virus following 3rd vaccination (Parts A and B of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Geometric Mean Titers Before 6-month Booster</measure>
    <time_frame>Before 6-month booster</time_frame>
    <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Geometric Mean Titers at 12 Months</measure>
    <time_frame>at 12 months</time_frame>
    <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Geometric Mean Titers After 6-month Booster</measure>
    <time_frame>month 6 after dose 4</time_frame>
    <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Rift Valley Fever</condition>
  <arm_group>
    <arm_group_label>TSI-GSD 200 RVF Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TSI-GSD 200 RVF Vaccine</intervention_name>
    <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
    <arm_group_label>TSI-GSD 200 RVF Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Parts A &amp; B:

          -  At least 18 years old, or if active military duty, 17 years old,

          -  Females of childbearing potential must agree to have a urine pregnancy test within 48
             hours before receipt of each dose of vaccine. The test results must be negative.
             Females will be advised not to become pregnant for 3 months after the primary series
             and each booster dose, and must not be breast-feeding,

          -  Subject must be actively enrolled in the SIP to be vaccinated at USAMRIID or be
             otherwise authorized (with documentation) by the DOD

          -  Subjects must be at risk for exposure to RVF virus,

          -  Subjects must have an up-to-date (within 1 year) medical history, physical
             examination, and laboratory tests in their charts and be medically cleared for
             participation by an investigator. Examinations or tests may be repeated within 1 year
             at the discretion of the enrolling physician.

          -  Volunteer must have signed and dated the approved informed consent (Volunteer
             Agreement Explanation and Affidavit).

        Additional Inclusion Criteria for Part B:

        • Completion of primary series and any follow-up titer (PRNT80) &lt; 1:40 from the current or
        a previous RVF IND 365 protocol.

        Exclusion Criteria

        Parts A &amp; B:

          -  Clinically significant abnormal lab results including evidence of Hepatitis C,
             Hepatitis B or carrier state, or elevated liver function tests.

          -  Personal history of immunodeficiency or current treatment with immunosuppressive
             medication, at the discretion of the physician.

          -  Confirmed HIV infection.

          -  Any medical condition that, at the discretion of the physician, may jeopardize the
             safety of the volunteer.

          -  Any serious or life-threatening allergies to any component of the vaccine: formalin,
             human serum albumin, neomycin, streptomycin

          -  Administration of any other vaccine within 28 days of any dose of RVF vaccine.

          -  Any unresolved adverse event resulting from a previous immunization.

        Additional Exclusion Criteria for Part B:

        • An adequate PRNT80 (≥ 1:40) after completion of primary series.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janice Rusnak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USAMRIID Medical Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.S. Army Medical Research Institute of Infectious Diseases</name>
      <address>
        <city>Fort Deterick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <results_first_submitted>February 22, 2017</results_first_submitted>
  <results_first_submitted_qc>June 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2017</results_first_posted>
  <disposition_first_submitted>February 2, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 3, 2017</disposition_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemorrhagic Fever, Viral Infections, Neurologic diseases, Arbovirus Infections, RVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Coccidioidomycosis</mesh_term>
    <mesh_term>Coccidiosis</mesh_term>
    <mesh_term>Rift Valley Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>278 subjects were enrolled at USAMRIID to participate</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TSI-GSD 200 RVF Vaccine</title>
          <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline includes all subjects vaccinated and doesn't account for drop outs, deviations, and withdraws. Demographics weren't given in Final Clinical Study Report. Numbers are reliant on numbers of females and males receiving vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>TSI-GSD 200 RVF Vaccine</title>
          <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.
TSI-GSD 200 RVF Vaccine: Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety: All Incidences of Erythema</title>
        <description>Collect data on the occurrence of AEs and SAEs in reference to Erythema (most frequently reported AE) in parts A and B of the study</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TSI-GSD 200 RVF Vaccine</title>
            <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: All Incidences of Erythema</title>
          <description>Collect data on the occurrence of AEs and SAEs in reference to Erythema (most frequently reported AE) in parts A and B of the study</description>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Geometric Mean Titers After 3rd Vaccination</title>
        <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) antibodies to RVF virus following 3rd vaccination (Parts A and B of study)</description>
        <time_frame>28 days after dose 3</time_frame>
        <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
        <group_list>
          <group group_id="O1">
            <title>TSI-GSD 200 RVF Vaccine</title>
            <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Geometric Mean Titers After 3rd Vaccination</title>
          <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) antibodies to RVF virus following 3rd vaccination (Parts A and B of study)</description>
          <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" lower_limit="29.6" upper_limit="75.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" lower_limit="43.6" upper_limit="128.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Geometric Mean Titers Before 6-month Booster</title>
        <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B</description>
        <time_frame>Before 6-month booster</time_frame>
        <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
        <group_list>
          <group group_id="O1">
            <title>TSI-GSD 200 RVF Vaccine</title>
            <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Geometric Mean Titers Before 6-month Booster</title>
          <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B</description>
          <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="4.7" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="8.2" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Geometric Mean Titers at 12 Months</title>
        <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B.</description>
        <time_frame>at 12 months</time_frame>
        <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
        <group_list>
          <group group_id="O1">
            <title>TSI-GSD 200 RVF Vaccine</title>
            <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Geometric Mean Titers at 12 Months</title>
          <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B.</description>
          <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="20.1" upper_limit="118.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.4" lower_limit="23.1" upper_limit="101.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity: Geometric Mean Titers After 6-month Booster</title>
        <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B.</description>
        <time_frame>month 6 after dose 4</time_frame>
        <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
        <group_list>
          <group group_id="O1">
            <title>TSI-GSD 200 RVF Vaccine</title>
            <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity: Geometric Mean Titers After 6-month Booster</title>
          <description>Measurement is the 80% plaque-reduction neutralization titer (PRNT80) for study Parts A and B.</description>
          <population>Population is based on responders (defined as a subject achieving a PRNT80 &gt;1:40)</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.8" lower_limit="140.5" upper_limit="319.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female: GMT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.0" lower_limit="128.0" upper_limit="279.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Annuals done for 5 years</time_frame>
      <desc>Of the 278 subjects enrolled, 153 subjects received at least 1 vaccination of Rift Valley Fever Vaccine, Inactivated, Dried (TSI-GSD 200) and 125 subjects were enrolled in the study but did not receive RVF vaccine. Each dose (primary, booster, or supplemental) consisted of 1.0 mL of vaccine delivered subcutaneously in the upper outer aspect of the arm (triceps area).</desc>
      <group_list>
        <group group_id="E1">
          <title>TSI-GSD 200 RVF Vaccine</title>
          <description>Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to &lt; 1:40.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness during physcial assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst exicision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Obstructive sleep apnea surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Back surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Meniscus repair surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Partial sigmoidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Laproscopic surgery for RLQ pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Left nephrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Swollen neck glands</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tender lymph nodes</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tight chest</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pressure</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Scratchy throat</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Stomach ache</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>GI problems</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Stomach virus</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Abdomen pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bil umbilial hernias</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>warm</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Axillary tenderness</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neck swollen</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Absence from work</sub_title>
                <description>No data</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pressure</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Warm</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <description>Probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Burning and pinching</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hives</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper eyelid swollen</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Face swelling</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chest congestion</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nail fungus</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pinkeye</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Abcess</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Lacerations</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Admittance</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bump on right arm</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Knee injury</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Itchy bumps on arms</sub_title>
                <description>Probably related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Eye trauma</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tender at site</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Warmth at site</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Soreness</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Hot at site</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tender to touch</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pain at site</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Swelling at site</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated B/P</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>URI</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Stiff neck</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Probably related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Light headedness</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Light headedness</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Foggy head</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Feeling faint</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Flashes of light</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Tingling</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hoarseness</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urination discomfort</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Stuffy nose</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Stuffy nose</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dry cough</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Dry cough</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Runny nose</sub_title>
                <description>Possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Head cold</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Unlikely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper eyelid pain to touch</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Upper eyelid itchy</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="153"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Definitely related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff screw removal</sub_title>
                <description>Unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="153"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janice Rusnak, MD</name_or_title>
      <organization>USAMRIID Medical Division</organization>
      <phone>301-619-4156</phone>
      <email>janice.rusnak@amedd.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

